Abstract: Chronic treatment of rats with ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) results in tolerance to its acute behavioral effects. In a previous study, 21-day ⌬ 9 -THC treatment in rats decreased cannabinoid activation of G proteins in brain, as measured by in vitro autoradiography of guanosine-5Ј 
Two types of cannabinoid receptors, CB 1 (Matsuda et al., 1990) and CB 2 (Munro et al., 1993) , have been cloned, with CB 1 receptors the predominant cannabinoid receptors in brain (Pertwee, 1997) . Cannabinoid compounds exert their CNS effects by binding to brain cannabinoid receptors (Compton et al., 1993) to activate G iand G o -type G proteins (Howlett et al., 1986; Devane et al., 1988) . Receptor activation of G proteins can be measured by agonist-stimulated binding of the hydrolysis-resistant GTP analogue, guanosine-5Ј-O-(3-[
35 S]thiotriphosphate) ([ 35 S ]GTP␥S), to G ␣ subunits in membranes (Hilf et al., 1989; Lorenzen et al., 1993; Traynor and Nahorski, 1995; Selley et al., 1996) or brain sections (Sim et al., 1995) . This technique has been used previously to demonstrate that ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC), the primary active constituent of marijuana (Gaoni and Mechoulam, 1964) , is a low-efficacy partial agonist at brain cannabinoid receptors because it stimulates only 20% as much [ 35 S]GTP␥S binding as the synthetic ligands WIN 55212-2 or levonantradol (Sim et al., 1996a; Burkey et al., 1997; Breivogel et al., 1998) .
Chronic administration of cannabinoids results in tolerance to their acute behavioral effects (Abood et al., 1993; Oviedo et al., 1993; Rodríguez de Fonseca et al., 1994; Deadwyler et al., 1995; Fan et al., 1996; Romero et al., 1997; Rubino et al., 1997) , and the degree of tolerance to each effect varies (Fan et al., 1994 (Fan et al., , 1996 . Measurement of the underlying changes in cannabinoid receptors that accompany tolerance has yielded variable results. Abood et al. (1993) found no changes in cannabinoid receptor binding or CB 1 mRNA in homogenates of whole mouse brain. However, region-specific changes in rat brain cannabinoid receptors and CB 1 mRNA have been reported after chronic ⌬ et al ., 1997 , 1998a Zhuang et al., 1998; Corchero et al., 1999) . Several studies have examined in vitro CB 1 receptor function following chronic cannabinoid treatment. Fan et al. (1996) reported a 50% reduction in [ 3 H]CP55940 binding sites in cerebellar membranes, but no desensitization of cannabinoid inhibition of adenylyl cyclase. Sim et al. (1996a) found region-specific decreases in cannabinoid-stimulated [ 35 S]GTP␥S binding to brain sections, which has been confirmed recently by other laboratories (Romero et al., 1998a; Corchero et al., 1999) .
Behavioral studies by Deadwyler et al. (1995) showed time-dependent tolerance to the memory-disruptive effects of daily ⌬ 9 -THC injections that was complete within 30 days. Using the same treatment paradigm, our laboratory demonstrated decreases in cannabinoid receptor activation of G proteins in a number of regions of rat brain using agonist-stimulated [ 35 S]GTP␥S autoradiography (Sim et al., 1996a) . However, none of the previous studies have determined the rate at which these changes in cannabinoid receptors and cannabinoid receptor activation of G proteins occurred across different brain regions. Moreover, it is not known whether these alterations in ligand binding occurred as a result of changes in the number (B max ) or affinity (K D ) of binding sites, or a change in the potency (EC 50 ) or efficacy (E max ) of cannabinoids to activate G proteins. The present study was performed to extend previous work by examining the time course of the adaptations of brain cannabinoid receptors and receptor activity following 3-, 7-, 14-, and 21-day treatments with ⌬ 9 -THC. The same treatment paradigm has been used by Zhuang et al. (1998) to investigate the effects of ⌬ 9 -THC treatment on CB 1 receptor mRNA in the same brain regions examined in this study. The results from these two studies provide a comprehensive, region-specific examination of the adaptation of cannabinoid receptors in rat brain to chronic ⌬ 9 -THC treatment. 9 -THC treatment ⌬ 9 -THC was dissolved in ethanol and prepared for injection as previously described (Heyser et al., 1993) . The ethanol solution was suspended in a 1:4:1 ratio with Pluronic F68 detergent in ethanol and saline, and the ethanol was evaporated under a stream of nitrogen gas. The ⌬ 9 -THC was diluted to 10 mg/ml in saline for injection. Animals received a single daily intraperitoneal injection of 10 mg/kg ⌬ 9 -THC or an equal volume of vehicle (control) for 3, 7, 14, or 21 days. Animals were killed by decapitation 24 h after the last injection. Brains were removed and hemisected along the midline; the left half was used for autoradiography, and the right was dissected for membrane assays, as described below.
MATERIALS AND METHODS

Materials
[ 35 S]GTP␥S autoradiography
Brains were immersed in isopentane at Ϫ35°C. Twentymicrometer horizontal sections were cut on a cryostat, thawmounted onto gelatin-coated slides, and stored at Ϫ80°C until use. Sections were rinsed in assay buffer [50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0.1% (wt/vol) bovine serum albumin (BSA), pH 7.4] at 25°C for 10 min and then with 2 mM GDP in assay buffer at 25°C for 15 min. They were then incubated with 0.04 nM [
35 S]GTP␥S and 2 mM GDP in the presence or absence of 10 M WIN 55212-2 in assay buffer at 25°C for 2 h. For all assays, WIN 55212-2 was dissolved at 10 mM in dimethyl sulfoxide and then diluted in assay buffer before addition to the assay. Basal [
35 S]GTP␥S binding was assessed in the absence of agonist on adjacent sections. Slides were rinsed twice in cold 50 mM Tris buffer, pH 7.4, and once in deionized water, dried, and exposed to film for 48 h. Films were digitized with a Sony XC-77 video camera and analyzed using the NIH Image program for Macintosh computers. Images were quantified by densitometric analysis with 14 C-labeled standards. Values are expressed as femtomoles of radioligand bound per gram of tissue and corrected for 35 S based upon incorporation of 35 S into brain paste standards (Sim et al., 1996b) .
[ 3 H]WIN 55212-2 receptor autoradiography
Brains were processed as described above. Sections were preincubated in 20 mM HEPES with 0.5% (wt/vol) BSA and 1 mM MgCl 2 , pH 7.0, for 20 min at 30°C and then incubated in 1 nM [ 3 H]WIN 55212-2 in this buffer for 80 min at 30°C. Nonspecific binding was assessed in the presence of 1 M unlabeled WIN 55212-2 on adjacent sections. Slides were rinsed four times for 10 min each in the preincubation buffer at 25°C and then twice in deionized water at 4°C. Slides were dried thoroughly and exposed to Hyperfilm ␤max for 3 weeks. Films were analyzed as described above.
3 H-labeled standards were used for quantification, and values are expressed as femtomoles of radioligand bound per milligram of tissue. [
3 H]WIN 55212-2 provided ϳ90% specific binding in the regions of interest.
Membrane preparations
The cerebellum, hippocampus, and striatum plus globus pallidus (including caudate-putamen and globus pallidus) were dissected from the right half of each brain on ice and stored at Ϫ80°C. On the day of the assay, each sample was thawed and homogenized with a Tissumizer (Tekmar, Cincinnati, OH, U.S.A.) in cold assay buffer [50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0.1% (wt/vol) BSA, pH 7.4] and centrifuged at 48,000 g for 10 min at 4°C. Pellets were resuspended in assay buffer and then centrifuged at 48,000 g for 10 min at 4°C. Pellets were homogenized in assay buffer, preincubated for 10 min at 30°C in 0.004 U/ml adenosine deaminase (EC 3.5.4.4; Sigma) to remove endogenous adenosine, and then assayed for protein content (Bradford, 1976) before addition to assay tubes. All three membrane assays were performed using the same assay conditions simultaneously on each tissue preparation.
Agonist-stimulated [ 35 S]GTP␥S binding assays
For saturation binding analysis, membranes were incubated with 0.5-20 nM unlabeled GTP␥S in the presence or absence of 3 M WIN 55212-2. WIN 55212-2 concentration-effect analysis was performed by incubating membranes with 1-10,000 nM WIN 55212-2; each assay also included a single triplicate of 1 M PIA to measure adenosine receptor-stimulated [ 35 S]GTP␥S binding. All assays were conducted at 30°C for 2 h in assay buffer (see above) including 10 -15 g of membrane protein with 0.1% (wt/vol) BSA, 30 M GDP, and 0.05 nM [
35 S]GTP␥S in a final volume of 1 ml. Nonspecific binding was determined in the absence of WIN 55212-2 and the presence of 30 M unlabeled GTP␥S. Reactions were terminated by rapid filtration under vacuum through Whatman GF/B glassfiber filters, followed by three washes with 4°C Tris buffer, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency for 35 S after overnight extraction of the filters in 4 ml of ScintiSafe Econo 1 scintillation fluid (Fisher).
[ 3 H]SR141716A receptor binding assays
Membranes were diluted with assay buffer and incubated under the same conditions as for the [ 35 S]GTP␥S binding assays. Saturation binding analyses were performed by incubating 3.5-5 g of membrane protein with 0.02-1 nM [ 3 H]SR141716A in the presence and absence of 1 M unlabeled SR141716A to determine nonspecific and specific binding, respectively. SR141716A was dissolved at 10 mM in 95% ethanol and then diluted in assay buffer (see above) before addition to the assay. Assays were conducted in assay buffer for 2 h at 30°C and included 0.1% (wt/vol) BSA, 30 M GDP, and 0.05 nM unlabeled GTP␥S. Reactions were terminated by rapid filtration under vacuum through Whatman GF/B glass-fiber filters that had been soaked in Tris buffer, pH 7.4, containing 0.5% (wt/vol) BSA, followed by three washes with 4°C Tris buffer, pH 7.4, containing 0.05% (wt/vol) BSA. Bound radioactivity was determined (at 45% efficiency for 3 H) as above. 35 S]GTP␥S autoradiography revealed high levels of cannabinoid receptor-activated G proteins in the caudate-putamen, globus pallidus, hippocampus, cerebellum, and cortex ( Fig. 1) . Four regions were analyzed densitometrically to correspond to membrane binding assays: cerebellum, hippocampus, caudate-putamen, and globus pallidus; autoradiographic results presented as striatum plus globus pallidus are data pooled from caudate-putamen and globus pallidus. Basal 3 H]WIN 55212-2 to examine the time course of the effects of chronic ⌬ 9 -THC treatment on cannabinoid receptor binding. High levels of cannabinoid receptors were found in the same regions described above: cerebellum, hippocampus, caudate-putamen, globus pallidus, and cortex (Fig. 1) . Qualitatively, the time course of receptor down-regulation was similar to that of desensitization measured in the [ 35 S]GTP␥S binding assay. However, in most regions, the magnitude of the decrease in receptor binding was less than the decrease in cannabinoid-activated G proteins. Representative autoradiograms are shown in Fig. 1 , and cannabinoid receptor binding values are presented in Table 2 . In the hippocampus, no significant decrease in cannabinoid receptor binding was detected until day 7, at which time it was 76% of control and remained at this level through days 14 and 21 ( p Ͻ 0.001). A similar time course was seen in the cerebellum, where cannabinoid receptor binding was reduced significantly from control at days 7, 14, and 21 ( p Ͻ 0.05), to ϳ80% of control. No significant changes were detected in the globus pallidus at any time point. In the caudate-putamen, decreased cannabinoid receptor binding was measured primarily in the ventral part of the region. The level of cannabinoid receptor binding in the caudate-putamen decreased to ϳ76% of control at day 7 ( p Ͻ 0.005). The level of receptor binding increased somewhat at day 14, and then returned to 79% of control at day 21 ( p Ͻ 0.005). Analysis of pooled data from the caudate-putamen and globus pallidus (designated as striatum plus globus pallidus) revealed that cannabinoid receptor binding decreased to ϳ85% of control at days 7 and 21 ( p Ͻ 0.05). Pooled data from the striatum plus globus pallidus, hippocampus, and cerebellum are presented in Fig. 2 .
Analysis of cannabinoid-stimulated [ 35 S]GTP␥S binding and cannabinoid receptor binding in membrane homogenates
Membrane assays were performed in cerebellum, hippocampus, and striatum plus globus pallidus to determine whether changes in receptor and [
35 S]GTP␥S binding observed in sections resulted from changes in binding site number (B max ) or affinity (K D ) or agonist potency (EC 50 ) or efficacy (E max ) in a homogeneous preparation of a given brain region. All samples from each region were assayed for cannabinoid activation of G proteins by [ 35 S]GTP␥S binding using two assays: concentrationeffect curves of WIN 55212-2 to determine whether chronic ⌬ 9 -THC treatment affected agonist potency and efficacy for G-protein activation (Selley et al., 1997) , and saturation analysis of net WIN 55212-2-stimulated [ 35 S]GTP␥S binding to determine whether desensitization changed the ability of the agonist to increase the affinity of G ␣ for [ 35 S]GTP␥S (i.e., apparent K D ) or to stimulate a maximal number of G ␣ (i.e., apparent B max ) (Breivogel et al., 1997a (Fig. 3) . These results showed no significant effect of chronic Nonlinear regression analysis of WIN 55212-2 concentration-effect curves revealed that the effect of agonist in all three regions was better fit to two-component sigmoidal curves than to single-component curves. Thus, both high-and low-potency EC 50 and E max values were determined for the stimulation of [
35 S]GTP␥S binding (Fig. 3) . The high-potency sites exhibited mean EC 50 values of 12.4 Ϯ 2.9 nM, 9.3 Ϯ 2.8 nM, and 7.4 Ϯ 6.5 nM for WIN 55212-2 in control cerebellum, hippocampus, and striatum plus globus pallidus, respectively. The low-potency sites in control tissue displayed EC 50 values for WIN 55212-2 of 453 Ϯ 75 nM in cerebellum, 459 Ϯ 37 nM in hippocampus, and 265 Ϯ 178 nM in striatum plus globus pallidus. Comparison of the basal levels of [ 35 S]GTP␥S binding (determined in the absence of WIN 55212-2) and WIN 55212-2 EC 50 values between tissue from control and ⌬ 9 -THC-treated animals from each brain region revealed significant differences in neither basal binding nor EC 50 values, indicating no detectable effects of residual ⌬ 9 -THC in the membranes. Although the chronic ⌬ 9 -THC treatment had no effect on the EC 50 values of WIN 55212-2-stimulated [
35 S]GTP␥S binding, the apparent potency of cannabinoids to activate G proteins was decreased because a higher concentration of drug would be required to obtain the same effect observed in control tissue (see Fig. 3 ). This apparent decrease in potency could manifest as tolerance to cannabinoids in chronically treated whole animals.
High-and low-potency E max values for all three regions are presented in Table 3 . ⌬ 9 -THC treatment did not result in significant changes in the E max values for cerebellum, except for a small decrease in the high-potency E max value at 7 days, which was not observed at 14 or 21 days. The hippocampus showed significant decreases ( p Ͻ 0.005) in high-potency E max values at all treatment times from days 3 to 21 (40 -45% decreases), but no significant effect of the ⌬ 9 -THC treatment on low-potency E max values (ANOVA, p ϭ 0.13). (Fig. 3) , none of the decreases in the high-potency (40% at day 21, p ϭ 0.51) or low-potency (31% at day 21, p ϭ 0.14) E max values reached statistical significance.
[ 35 values for cannabinoid-activated G proteins in each region. These values are termed "apparent" because of the presence of GDP in the assay, which is necessary for agonist stimulation of [ 35 S]GTP␥S binding, but competes for [ 35 S ]GTP␥S binding at the guanine nucleotide binding site of the G protein (Breivogel et al., 1998) . In contrast to results obtained in purified G proteins, however, the binding of [
35 S]GTP␥S to native membranes is reversible (Hilf et al., 1992; Breivogel et al., 1998) , allowing the data to be analyzed under the assumptions of saturable and reversible ligand binding.
Net agonist-stimulated values are obtained by subtracting the basal binding values from those obtained in the presence of agonist at each concentration of GTP␥S. Net WIN 55212-2-stimulated [
35 S]GTP␥S binding saturation analyses (Fig. 4) showed similar effects of ⌬ 9 -THC treatment to the WIN 55212-2 concentration-effect of [
35 S]GTP␥S binding. ⌬ 9 -THC treatment had no effect on [
35 S]GTP␥S binding apparent K D values in any region, which had mean values of 1.8 Ϯ 0.3 nM, 3.4 Ϯ 0.5 nM, and 2.0 Ϯ 0.2 nM for control cerebellum, hippocampus, and striatum plus globus pallidus, respectively. Furthermore, there was no effect of ⌬ 9 -THC treatments on the levels of basal [
35 S]GTP␥S binding in these assays, as in the concentration-effect assays. Apparent B max values in cerebellum were not affected by the chronic ⌬ 9 -THC treatment (ANOVA, p ϭ 0.20). In striatum plus globus pallidus, there was no decrease in apparent B max values until day 21 (21% decrease from control), the same time point where the significant decrease in E max was observed; however, the decrease in apparent B max failed to reach statistical significance ( p ϭ 0.38 by Dunnett's test). Apparent B max values decreased by 30 -45% in hippocampus from days 7 to 21 ( p Ͻ 0.05 at day 7 and p Ͻ 0.005 at days 14 and 21) ( Table 3 ). These results indicated that the chronic ⌬ 9 -THC-induced decreases in the maximal effect of the agonist (E max ) seen in the WIN 55212-2 concentration-effect curves for hippocampus were due to a decrease in the number of G proteins being activated by WIN 55212-2 (apparent B max ), and not a change in the apparent affinity of the WIN 55212-2-activated G proteins for [ 35 
To determine whether the effects of chronic ⌬ 9 -THC treatment were specific to cannabinoid receptors, [ 35 S]GTP␥S assays were conducted in the presence of a maximally effective concentration of the adenosine A1 receptor agonist, PIA. In control membranes, PIA stimulated [
35 S]GTP␥S binding by 280 Ϯ 6% in cerebellum, 230 Ϯ 10% in hippocampus, and 102 Ϯ 11% in striatum plus globus pallidus. In contrast to its effects on cannabinoid-stimulated [
35 S]GTP␥S binding, chronic ⌬ 9 -THC had no effect on PIA-stimulated [
35 S]GTP␥S binding at any treatment time in any region (data not shown). These results are analogous to those obtained previously where chronic ⌬ 9 -THC treatment had no effect on GABA Bstimulated [
35 S]GTP␥S binding to sections (Sim et al., 1996a) .
Cannabinoid receptor binding. The number and affinity of cannabinoid receptors were quantified by saturation binding analysis of the CB 1 -selective antagonist (Table  4) . Mean K D values in control tissue were not significantly different among regions with values of 0.25 Ϯ 0.07 nM, 0.12 Ϯ 0.02 nM, and 0.14 Ϯ 0.02 nM in cerebellum, hippocampus, and striatum plus globus pallidus, respectively. Both cerebellum and hippocampus showed significant decreases in [ 3 H]SR141716A B max (ANOVA, p ϭ 0.011 and 0.001, respectively) beginning at 3 days. ⌬ 9 -THC treatments resulted in maximal decreases in receptor numbers of 50% for cerebellum and 55% for hippocampus at 21 days ( 
DISCUSSION
The present study extends the findings of Sim et al. (1996a) (Romero et al., 1997 (Romero et al., , 1998a Corchero et al., 1999) , this is the first study to determine systematically the time course of cannabinoid receptor desensitization and down-regulation in multiple brain regions simultaneously. Furthermore, this is the first study to correlate the effects of chronic ⌬ 9 -THC on cannabinoid receptors and receptor-stimulated [
35 S]GTP␥S binding between brain sections and membranes, to provide a complete assessment of changes in receptor/G-protein coupling. Although these results are generally consistent with the results of studies by other laboratories, some important differences should be addressed. Romero et al. (1998a) have reported that a 5 day-treatment with ⌬ 9 -THC does not significantly affect WIN 55212-2-stimulated [ 35 S]GTP␥S binding in the caudate-putamen or globus pallidus, whereas significant decreases in cannabinoid receptor binding were found in most brain regions examined, including caudate-putamen, but not globus pallidus. These findings are consistent with the present results, except that a significant decrease in cannabinoid receptor binding in caudate-putamen reported at 5 days by Romero et al. (1998a) Romero et al. (1998a) ; WIN 55212-2-stimulated [
35 S]GTP␥S binding was decreased significantly in the caudate-putamen from days 1 through 14 of ⌬ 9 -THC treatment. The reason for this discrepancy is not clear, but may result from differences in ⌬ 9 -THC treatment or in in vitro assay conditions between laboratories.
All of the previous studies of the effects of chronic ⌬ 9 -THC administration on brain cannabinoid receptors used single concentrations of radioligand binding to brain sections, which did not allow for a distinction between loss of ligand binding sites and loss of ligand binding affinity (Sim et al., 1996a; Romero et al., 1997 Romero et al., ,1998a Corchero et al., 1999) . The current study indicates that decreases in cannabinoid-stimulated [ 35 S]GTP␥S binding and cannabinoid receptor binding were attributable to losses in the number of cannabinoid receptors and cannabinoid receptor-activated G proteins. These results support and extend previous work on the effects of chronic ⌬ 9 -THC on cannabinoid receptor/G protein coupling. Furthermore, these data support previous results from our laboratory (Breivogel et al., 1997b) , which indicate that cannabinoid receptors exhibit quantitative differences in measurements of signal transduction responses depending upon their regional localization.
An important consideration in this study was that residual ⌬ 9 -THC might remain in the tissue, due to its lipophilic nature. As we have found that ⌬ 9 -THC is a partial cannabinoid agonist (Sim et al., 1996a) , this is an important concern because residual ⌬ 9 -THC could decrease WIN 55212-2-stimulated [
35 S]GTP␥S binding. In the previous study by Sim et al. (1996a) , stringent controls were included that excluded this possibility. The results of the current study further indicate that residual ⌬ 9 -THC is not present because there were no differences between control and ⌬ 9 -THC-treated samples in ( (Sim et al., 1996a) nor adenosine A1 (present results) activation of G proteins was affected by chronic ⌬ 9 -THC treatment. Qualitatively similar results were obtained in both isolated membranes and brain sections. In both preparations, the fastest and greatest decrease in cannabinoid receptor binding and receptor-stimulated [
35 S]GTP␥S binding occurred in the hippocampus, with a slower response in cerebellum, and the smallest and slowest response in striatum plus globus pallidus. However, some important differences were seen using the two methods; in particular, desensitization was greater in magnitude using [ 35 S]GTP␥S autoradiography compared with membrane binding assays, whereas the degree of apparent receptor down-regulation was greater in membranes than in sections. It is possible that these discrepancies were due to technical differences. For example, each preparation provides different degrees of anatomical resolution, and membranes are prepared from dissected regions in which microheterogeneities may be lost. Furthermore, brain sections preserve cellular organization, whereas soluble components and subcellular compartmentalization are lost during homogenization of membranes. Thus, differences in desensitization may have been due to dephosphorylation or to loss of components, such as arrestin, that mediate receptor/G-protein uncoupling (Lefkowitz et al., 1992) , or loss of internalized CB 1 receptors (Wenzhen et al., 1999 (Skaper et al., 1996) or undiscovered cannabinoid receptor types in brain, the fact that receptor binding was measured in brain sections with a nonselective agonist, and in membranes with a CB 1 -selective antagonist, may explain the lower degree of down-regu- 
